OKYO Pharma (OKYO) Common Equity (2021 - 2026)
OKYO Pharma (OKYO) posted quarterly Common Equity of $12.3 million for Q1 2026, up 322.27% year-over-year from $2.9 million in Q1 2025, and up 461.17% quarter-over-quarter from -$3.4 million in Q3 2025.
OKYO Pharma (OKYO) Common Equity (2021 - 2026) Analysis & Trends
OKYO Pharma (OKYO) has reported Common Equity for 6 consecutive years, with $12.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Common Equity rose 322.27% year-over-year to $12.3 million; the TTM figure through Mar 2026 stood at $12.3 million (up 322.27% YoY), while the FY2026 annual figure was $12.3 million, up 322.27% from the prior year.
- Common Equity climbed to $12.3 million in Q1 2026 per OKYO's latest filing, from -$3.4 million in the prior quarter.
- Across five years, Common Equity topped out at $12.3 million in Q1 2026 and bottomed at -$7.2 million in Q3 2024.
- Historically, Common Equity has averaged -$1.8 million across 5 years, with a median of -$4.5 million in 2025.
- Annual changes were most pronounced in 2024 — Common Equity tumbled 186.36% — and 2026, when it jumped 322.27%.
- OKYO Pharma's Common Equity stood at $2.9 million in 2022, then sank by 301.48% to -$5.9 million in 2023, then declined by 21.68% to -$7.2 million in 2024, then jumped by 52.73% to -$3.4 million in 2025, then surged by 461.17% to $12.3 million in 2026.
- Business Quant data shows OKYO's Common Equity at $12.3 million in Q1 2026, -$3.4 million in Q3 2025, and -$5.5 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.14 Bn | 132.29 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 87.02 Bn | 79.03 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 65.30 Bn | 60.12 Bn | 1.37 Bn | - |
| 4 | Moderna | 60.84 Bn | 55.70 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 42.15 Bn | 37.06 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.49 Bn | 28.18 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 28.78 Bn | 10.38 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.14 Bn | 26.31 Bn | - | 9.79 Bn |
| 10 | OKYO Pharma | 1.50 Bn | 1.50 Bn | - | 12.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 12.34 Mn |
| Sep 30, 2025 | -3.42 Mn |
| Mar 31, 2025 | -5.55 Mn |
| Sep 30, 2024 | -7.23 Mn |
| Mar 31, 2024 | -5.88 Mn |
| Sep 30, 2023 | -5.94 Mn |
| Mar 31, 2023 | -2.05 Mn |
| Mar 31, 2022 | 2.95 Mn |
| Mar 31, 2021 | 5.32 Mn |